Cantor Fitzgerald downgraded Prothena (PRTA) to Neutral from Overweight without a price target Prothena announced that birtamimab’s Phase 3 AFFIRM trial in AL amyloidosis failed to meet its primary survival endpoint or either of two secondary endpoints, the analyst tells investors in a research note. Cantor says the news is “not surprising,” as it viewed AFFIRM as a high-risk study, and “applauds” the decision by the company to review all business operations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Hold Rating: Clinical Trial Challenges and Financial Pressures
- Prothena price target lowered to $81 from $110 at Piper Sandler
- Prothena’s Strategic Shift and Promising Alzheimer’s Pipeline Drive Buy Rating
- Prothena price target lowered to $14 from $30 at H.C. Wainwright
- Prothena price target lowered to $29 from $78 at Citizens JMP